@article{MTMT:36364226,
	title = {Application of Immune Checkpoint Inhibitors in Cancer},
	url = {https://m2.mtmt.hu/api/publication/36364226},
	author = {Chen, Zhijun and Song, Zihan and Den, Shichen and Zhang, Wei and Han, Mengjia and Lan, Tianhang and Du, Xiaokang and Ning, Jingyun and Chen, Xinhui and Lin, Haoming and Zhang, Rui},
	doi = {10.1002/mco2.70176},
	journal-iso = {MEDCOMM},
	journal = {MEDCOMM},
	volume = {6},
	unique-id = {36364226},
	year = {2025},
	eissn = {2688-2663}
}

@article{MTMT:37020309,
	title = {Rhabdomyolysis as a Predominant Multisystem Serious Immune-Related Adverse Event Induced by Sintilimab: A Case Report and Literature Review},
	url = {https://m2.mtmt.hu/api/publication/37020309},
	author = {Duan, Qingyuan and Zhang, Xueying and Li, Minjie},
	doi = {10.2147/CMAR.S564116},
	journal-iso = {CANCER MANAG RES},
	journal = {CANCER MANAGEMENT AND RESEARCH},
	volume = {17},
	unique-id = {37020309},
	issn = {1179-1322},
	year = {2025},
	eissn = {1179-1322},
	pages = {3383-3392}
}

@article{MTMT:35140697,
	title = {Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors},
	url = {https://m2.mtmt.hu/api/publication/35140697},
	author = {Gergely, Tamás G and Drobni, Zsófia and Sayour, Viktor Nabil and Ferdinandy, Péter and Varga, Zoltán},
	doi = {10.1007/s00395-024-01068-8},
	journal-iso = {BASIC RES CARDIOL},
	journal = {BASIC RESEARCH IN CARDIOLOGY},
	volume = {120},
	unique-id = {35140697},
	issn = {0300-8428},
	abstract = {Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by unleashing the power of the immune system against malignant cells. However, their use is associated with a spectrum of adverse effects, including cardiovascular complications, which can pose significant clinical challenges. Several mechanisms contribute to cardiovascular toxicity associated with ICIs. First, the dysregulation of immune checkpoints, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein-1 (PD-1) and its ligand (PD-L1), and molecular mimicry with cardiac autoantigens, leads to immune-related adverse events, including myocarditis and vasculitis. These events result from the aberrant activation of T cells against self-antigens within the myocardium or vascular endothelium. Second, the disruption of immune homeostasis by ICIs can lead to autoimmune-mediated inflammation of cardiac tissues, manifesting as cardiac dysfunction and heart failure, arrhythmias, or pericarditis. Furthermore, the upregulation of inflammatory cytokines, particularly tumor necrosis factor-alpha, interferon-γ, interleukin-1β, interleukin-6, and interleukin-17 contributes to cardiac and endothelial dysfunction, plaque destabilization, and thrombosis, exacerbating cardiovascular risk on the long term. Understanding the intricate mechanisms of cardiovascular side effects induced by ICIs is crucial for optimizing patient care and to ensure the safe and effective integration of immunotherapy into a broader range of cancer treatment protocols. The clinical implications of these mechanisms underscore the importance of vigilant monitoring and early detection of cardiovascular toxicity in patients receiving ICIs. Future use of these key pathological mediators as biomarkers may aid in prompt diagnosis of cardiotoxicity and will allow timely interventions.},
	year = {2025},
	eissn = {1435-1803},
	pages = {187-205},
	orcid-numbers = {Drobni, Zsófia/0000-0002-1355-5318; Ferdinandy, Péter/0000-0002-6424-6806; Varga, Zoltán/0000-0002-2758-0784}
}

@article{MTMT:36464395,
	title = {Healthcare utilization in cancer patients treated with immune checkpoint inhibitors: a population-based study of all patients and 1-year survivors},
	url = {https://m2.mtmt.hu/api/publication/36464395},
	author = {Hsu, Chia-Lu and Hsu, Li-Fan and To, Sheng-Yin and Lee, Cho-Hao and Wen, Yuan-Liang and Yang, Hui-Wen and Chen, I-Wen and Kao, Li-Ting},
	doi = {10.1007/s00520-025-10127-2},
	journal-iso = {SUPPORT CARE CANCER},
	journal = {SUPPORTIVE CARE IN CANCER},
	volume = {33},
	unique-id = {36464395},
	issn = {0941-4355},
	year = {2025},
	eissn = {1433-7339}
}

@article{MTMT:35780405,
	title = {Nanoengineered immune check point inhibitors delivery for targeted brain cancer treatment: Current status and future perspectives},
	url = {https://m2.mtmt.hu/api/publication/35780405},
	author = {Liu, J. and Wang, Y. and Song, Z. and Zhang, Y.},
	doi = {10.1016/j.bcp.2025.116789},
	journal-iso = {BIOCHEMIC PHARMACOL},
	journal = {BIOCHEMICAL PHARMACOLOGY},
	volume = {233},
	unique-id = {35780405},
	issn = {0006-2952},
	abstract = {Brain tumors create special difficulties because of their position and the protective covering of blood brain barrier (BBB) that restricts efficient medication access. Treatment alternatives such as surgery and chemotherapy demonstrate poor performance against severe brain tumors. The use of immune checkpoint inhibitors (ICIs) hints at effective cancer therapy; however, their application to brain cancer faces challenges due to inefficient delivery through the BBB and the tumor's suppressive environment. Nanoengineering can increase the transport of ICIs to brain tumors. Numerous nano-delivery systems such as liposomes and micelles have explored ways to avoid the BBB via transcytosis and the EPR mechanism. Functionalization of nanocarriers enhances targeting tumor cells and improves treatment accuracy. New developments involve delivering ICIs together with adjuvants to change the TME and focusing on immune cells such as TAMs and Tregs to boost immunity against tumors. Nanoengineered ICIs have shown effective improvement in animal models by reducing toxicity and enhancing efficacy. Converting these successes into real clinical trials is not easy as they face regulatory concerns and safety challenges. Clinical trials currently examine the use of nanocarriers for treating brain cancer; however, scalability’ and ’long-term safety’ continue to pose challenges. Future approaches will focus on combining customized medicine with advanced nanotechnology and AI to refine treatment methods. Despite obstacles ahead, nanotechnology-based ICIs offer a hopeful approach to enhance brain cancer efficacy and address existing therapeutic constraints. © 2025 Elsevier Inc.},
	year = {2025},
	eissn = {1873-2968}
}

@article{MTMT:36814355,
	title = {Immunotherapy in cancer: novel approaches and future perspectives},
	url = {https://m2.mtmt.hu/api/publication/36814355},
	author = {Stefanska, Barbara and Rabbani, Shafaat A.},
	doi = {10.1111/bph.70296},
	journal-iso = {BR J PHARMACOL},
	journal = {BRITISH JOURNAL OF PHARMACOLOGY},
	unique-id = {36814355},
	issn = {0007-1188},
	year = {2025},
	eissn = {1476-5381}
}

@article{MTMT:36814357,
	title = {Optimizing management of immune checkpoint inhibitor-induced pancreatic enzyme elevation: Risk-based strategies},
	url = {https://m2.mtmt.hu/api/publication/36814357},
	author = {Ting, Tsai Ling and Lee, Yuan-Ti},
	doi = {10.1111/jdv.70284},
	journal-iso = {J EUR ACAD DERMATOL},
	journal = {JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY},
	unique-id = {36814357},
	issn = {0926-9959},
	keywords = {pancreatitis; LIPASE; Adrenal Cortex Hormones; Exocrine Pancreatic Insufficiency; Drug-Related Side Effects and Adverse Reactions; immune checkpoint inhibitors},
	year = {2025},
	eissn = {1468-3083}
}

@article{MTMT:35925008,
	title = {Enhanced antitumor efficacy of bispecific antibody blocking PD-L1 and LAG-3 with doxorubicin: mechanism and safety evaluation},
	url = {https://m2.mtmt.hu/api/publication/35925008},
	author = {Zhang, Chenxing and Liu, Jiaxin and Gu, Tiejun and Meng, Xiangyu and Cai, Xiaoyi and Zhang, Jinfeng and Chen, Yan and Zhang, Daguang and Wu, Yongge},
	doi = {10.1007/s10549-025-07676-9},
	journal-iso = {BREAST CANCER RES TR},
	journal = {BREAST CANCER RESEARCH AND TREATMENT},
	volume = {211},
	unique-id = {35925008},
	issn = {0167-6806},
	keywords = {breast cancer; combination therapy; dox; PD-L1; LAG-3; Tumor immunotherapy},
	year = {2025},
	eissn = {1573-7217},
	pages = {637-648}
}